MG-262 (Z-Leu-Leu-Leu-B(OH)2): A Reversible, Cell-Permeable Proteasome Inhibitor for Precision Research

Executive Summary: MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a boronic acid-based, reversible proteasome inhibitor with an IC₅₀ of 122 nM against chymotryptic proteasome activity, enabling high-precision studies of protein degradation pathways (APExBIO, 2024). It is cell-permeable, allowing for both in vitro and in vivo research on apoptosis, cell cycle arrest, and signaling modulation (MG132.com). MG-262 interferes selectively with the ubiquitin-proteasome system, impacting processes relevant to cancer, inflammation, and neurodegeneration (Nature Metabolism 2025). The compound is soluble in DMSO (≥24.57 mg/mL) and ethanol (≥96.4 mg/mL) but not water. Proper storage at -20°C and immediate pre-use solution preparation are essential for experimental reproducibility (APExBIO, 2024).

Biological Rationale

Protein homeostasis in eukaryotic cells depends on the balance between protein synthesis and degradation. The ubiquitin-proteasome system (UPS) mediates targeted degradation of short-lived and abnormal proteins, regulating cell cycle progression, apoptosis, and signal transduction (Nature Metabolism 2025). Dysregulation of UPS activity is implicated in cancer, neurodegenerative diseases, and inflammatory conditions. Proteasome inhibitors such as MG-262 allow for the experimental interrogation of these pathways. By reversibly blocking the chymotryptic activity of the proteasome, MG-262 enables researchers to dissect specific steps in protein degradation and their downstream cellular consequences (MG132.com). Compared to irreversible inhibitors, MG-262 offers temporal control and reduced cytotoxicity, supporting dynamic studies of cell fate and signaling networks.

Mechanism of Action of MG-262 (Z-Leu-Leu-Leu-B(OH)2)

MG-262 is a peptide boronic acid compound with the sequence Z-Leu-Leu-Leu-B(OH)₂. The boronic acid moiety covalently yet reversibly interacts with the catalytic threonine of the 20S proteasome's chymotrypsin-like site (PS-341.com). This interaction blocks substrate access, inhibiting degradation of ubiquitinated proteins. The inhibition is reversible, as MG-262 can dissociate from the proteasome active site upon dilution or removal. The compound is cell-permeable, enabling efficient intracellular delivery. In cell-based systems, MG-262 induces cell cycle arrest, reduces DNA replication, and triggers apoptosis by perturbing proteostasis. Key downstream effects include upregulation of p21 and p27, loss of mitochondrial membrane potential, activation of caspase-3 and poly(ADP-ribose) polymerase, and modulation of MAP kinase pathways (Oprozomib.org). These features distinguish MG-262 as a versatile tool for dissecting complex biological responses to proteasome inhibition.

Evidence & Benchmarks

• MG-262 inhibits proteasome chymotryptic activity in vitro with an IC₅₀ of 122 nM, measured in standard biochemical assays (APExBIO, 2024).
• Induces dose-dependent reduction of cell viability and proliferation in fibroblasts and cancer cell lines by causing G1/S cell cycle arrest (PS-341.com).
• Triggers apoptosis evidenced by mitochondrial membrane depolarization, caspase-3 activation, and PARP cleavage in vitro (Oprozomib.org).
• Inhibits osteoclast differentiation in a concentration-dependent manner in primary cell culture studies (Map-Kinase-Fragment.com).
• Reduces proteasome activity in multiple murine organs after intravenous administration, confirming in vivo efficacy (Nature Metabolism 2025).

Common Pitfalls or Misconceptions

• MG-262 is not suitable for irreversible proteasome inhibition studies; its action is reversible and time-sensitive.
• It is insoluble in water; use DMSO or ethanol for stock solutions to ensure accurate dosing (APExBIO).
• Solutions are unstable over time; always prepare fresh aliquots immediately before use.
• MG-262 selectively targets the chymotryptic site; it does not broadly inhibit all protease activities in the cell.
• In vivo utility depends on dosing, route of administration, and tissue permeability; systemic toxicity profiles must be considered in animal studies.

Applications, Limits & Misconceptions

MG-262 serves as a research tool in cancer, inflammatory, and neurodegenerative disease models by selectively inhibiting the proteasome. It is instrumental in apoptosis research, cell cycle arrest studies, and proteostasis investigations. The compound has been used to study the impact of UPS modulation in skeletal muscle atrophy, as described in recent peer-reviewed research (Nature Metabolism 2025). However, MG-262 is not intended for irreversible inhibition workflows or non-specific protease studies. Its efficacy depends on cell permeability, dosing, and solution stability. For a more detailed review of mechanistic aspects and comparison with other inhibitors, see our article Reversible Proteasome Inhibition: A Strategic Frontier for Translational Research (this article emphasizes advances in workflow precision and expands on the cell cycle arrest mechanisms compared to the present piece). For a focused discussion on MAP kinase signaling and apoptosis, refer to MG-262: Unraveling Proteasome Inhibition in Advanced Signaling Pathways (the current article provides updated in vivo benchmarks and solubility data).

Workflow Integration & Parameters

MG-262 is supplied by APExBIO as SKU A8179 (product page). For in vitro use, dissolve in DMSO (≥24.57 mg/mL) or ethanol (≥96.4 mg/mL). Prepare working solutions fresh before each experiment due to solution instability. Store dry compound at -20°C. Typical working concentrations range from 10 nM to 1 μM, depending on cell type and assay sensitivity. For in vivo studies, administer via intravenous injection and monitor tissue-specific effects. Proteasome inhibition can be quantified by fluorogenic peptide substrates or immunoblotting for ubiquitinated proteins. Always include appropriate vehicle and negative controls. MG-262 is compatible with cell viability assays, flow cytometry for apoptosis markers, and proteomic analyses. For more detailed protocols and comparison to related inhibitors, see MG-262: A Reversible Proteasome Inhibitor for Disease Models (this piece clarifies the solubility and storage constraints relative to prior summaries).

Conclusion & Outlook

MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a robust, reversible, and cell-permeable proteasome inhibitor that enables high-resolution studies of protein degradation, cell cycle, and apoptosis. Its selectivity, potency, and compatibility with both in vitro and in vivo workflows make it a preferred reagent for investigating the ubiquitin-proteasome system in cancer, inflammatory, and neurodegenerative models. By providing temporal control and minimizing off-target effects, MG-262 supports the development of next-generation research on proteostasis and targeted therapeutic discovery. For detailed documentation and ordering information, visit the APExBIO MG-262 product page.